C-Path welcomes Sanofi to its Type 1 Diabetes Consortium to help advance drug development

(Press-News.org) TUCSON, Ariz., August 9, 2023 — Critical Path Institute (C-Path) announced today that Sanofi, a global leader in immunology and diabetes care, has joined its Type 1 Diabetes Consortium (T1DC). Sanofi joins T1DC as part of its commitment to push the boundaries of innovation to improve the lives of those with diabetes.

T1DC was established in 2017 with the goal to significantly advance the drug development landscape for T1D prevention and treatment. The consortium achieves this by fostering collaborative relationships within the broader T1D community and sharing data, knowledge and resources to promote the development and regulatory endorsement of novel drug development tools.

“Sanofi is committed to making a difference in the lives of those impacted by type 1 diabetes,” said Niels Porksen, Therapeutic Area Head DCV Development, Sanofi. “We are thrilled to join forces with the Critical Path Institute’s T1DC, as this collaboration underscores our dedication to advancing innovative solutions. We believe that by sharing knowledge, resources and data with this esteemed consortium, we can help accelerate the development of novel therapies and improve outcomes for patients living with T1D.”

We hope that Sanofi’s participation will help expedite advancements in both T1D prevention and treatment of new-onset T1D and look forward to working with Sanofi on accelerating progress towards developing breakthrough therapies and enhancing patient outcomes.

“T1D poses a considerable burden to patients and new and better therapies that improve the lives of those at risk or living with T1D are desperately needed,” said Elnaz Atabakhsh, Ph.D., Executive Director of C-Path’s T1DC. “The T1D Consortium works to accelerate the process to develop these therapies, a goal that can only be achieved through rich collaboration between scientists, clinicians, patients, regulators and key industry members including Sanofi. Sanofi’s experience and expertise will be invaluable to T1DC as we continue our efforts, and we are thrilled to have them join us as members of the T1D Consortium.”

Together, C-Path and Sanofi are committed to driving transformative change and achieving meaningful outcomes for patients.

About Critical Path Institute

Critical Path Institute (C-Path) is an independent, nonprofit established in 2005 as a public-private partnership, in response to the FDA’s Critical Path Initiative. C-Path’s mission is to lead collaborations that advance better treatments for people worldwide. Globally recognized as a pioneer in accelerating drug development, C-Path has established numerous international consortia, programs and initiatives that currently include more than 1,600 scientists and representatives from government and regulatory agencies, academia, patient organizations, disease foundations and pharmaceutical and biotech companies. With dedicated team members located throughout the world, C-Path’s global headquarters is located in Tucson, Arizona and C-Path’s Europe subsidiary is headquartered in Amsterdam, Netherlands. For more information, visit c-path.org.

Critical Path Institute is supported by the Food and Drug Administration (FDA) of the Department of Health and Human Services (HHS) and is 55% funded by the FDA/HHS, totaling $17,612,250, and 45% funded by non-government source(s), totaling $14,203,111. The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement by, FDA/HHS or the U.S. Government.

END